Promising Combo Therapy: OnabotulinumtoxinA & Atogepant for Migraines

Research Summary

The SYNERGY study, published in Cephalalgia, explores the effectiveness of combining onabotulinumtoxinA (BoNTA) and atogepant for chronic migraine (CM) treatment. In a real-world setting, 82 of 101 patients completed 24 weeks of this combination therapy, showing promising results. Monthly migraine days decreased by 6.5 days, with 45% achieving a ≥50% reduction. Acute medication usage was reduced by 6 days, and patients reported significant improvements in Headache Impact Test-6 scores and overall impressions of change. Anti-calcitonin gene-related peptide naïve patients benefited more than non-naïve ones. The combination therapy was well-tolerated, with no new safety concerns, suggesting potential for broader clinical application.

Study Details

📄 Title: Combination preventive therapy with onabotulinumtoxinA and atogepant for chronic migraine: A 24-week, prospective, real-world evaluation (SYNERGY study).

👥 Research Team: Iannone LF et al.

📚 Published In: Cephalalgia

📅 Publication Date: 2025 Dec

⚕️ Medical Disclaimer: This summary is generated automatically from recent migraine research. Always consult with healthcare professionals for medical advice.